## 10/505231 DT09 Rec'd PCT/PT0 .19 AUG 2004:

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0551-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known			
5000	34423 101 101111 1440743			Application Number	Not Yet Assigned		
l in	FORMATIO	N DIS	SCLOSURE	Filing Date	Concurrently Herewith		
S	TATEMENT	BY A	PPLICANT	First Named Inventor	Paul Richard Gellert		
				Art Unit	N/A		
	(Use as many sheets as necessary)			Examiner Name	Not Yet Assigned		
Sheet	1	of	1	Attorney Docket Number	ASZD-P01-724		

	U.S. PATENT DOCUMENTS								
Examiner	Cite	Document Number	Name of Patentee or	Pages, Columns, Lines, Where					
Initials*	No.1	Number-Kind Code <sup>2</sup> ( if known)	MM-DD-YYYY		Relevant Passages or Relevant Figures Appear				
JDA	AA	US-4,344,934	08-17-1982	Martin et al.					
JDA	AB	US-US 2003/0045537-A1	03-06-2003	Lee et al.					

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>6</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
JDA	BA	-WO 96/33980	10-31-1996	Gibson				
JDA	BB	-GB 2,306,885	05-14-1997	Poile				

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicants unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.usplo.gov">www.usplo.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-latter code (WIPO Standard ST.3). For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document. In the Indication of the year of the Tengen of the Emperor must precede the serial number of the patent document. In the Indication of the year of the Indication of the year of the Emperor must precede the serial number of the patent document. In the Indication of the year of Indication of Indicat

NON PATENT LITERATURE DOCUMENTS						
	T					
	book, city					

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Oraw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	Examiner Signature	/James Anderson/	Date Considered	07/18/2006
--	--------------------	------------------	--------------------	------------

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

## Application No. 10/505,231 Attorney Docket No. 056291-5174-US INFORMATION DISCLOSURE CITATION (se several sheets if necessary) PAGE 1 of 2 Applicants: GELLERT et al. JUL 2 8 2005 **EPTO Form 1449** Filing Date: August 19, 2004 Group Art Unit: 1615 **U.S. PATENT DOCUMENTS Filing Date** Class Sub-Class Document No. Date Name Initial Lee et al. March 6, 2003 JDA 2003/045537 Curatolo et al. 2002/009494 January 24, 2002 2. May 7, 2002 Chen et al. 3. 6,383,471 6,294,192 September 25, 2001 Patel et al. 4. June 19, 2001 Shenoy et al. 5. 6,248,771 May 20, 1997 Davis et al. 5,631,248 6. April 1, 1997 Barker 7. 5,616,582 September 24, 1996 Al-Razzak et al. 8. 5,559,158 5,457,105 October 10, 1995 Barker 9. November 3, 1987 Beatty et al. 4,704,284 10. Martin et al. August 17, 1982 JDA 11. 4,344,934 FOREIGN PATENT DOCUMENTS Sub-Class Class Translation Date Country Document No. April 24, 2003 WIPO 12. WO 03/32956 JDA WO 03/00294 January 3, 2003 WIPO 13. WIPO November 14, 2002 14. WO 02/89773 WIPO WO 02/20020 March 14, 2002 15. WIPO WO 02/02534 January 10, 2002 16. WIPO WO 01/76586 October 18, 2001 17. WO 01/47495 July 5, 2001 WIPO 18. WIPO January 18, 2001 WO 01/04102 19. October 12, 2000 **WIPO** 20. WO 00/59475 WIPO 21. WO 00/00179 January 6, 2000 September 11, 1998 WIPO 22. WO 98/38984 WIPO December 5, 1996 WO 96/38131 23. WIPO WO 96/33980 October 31, 1996 24. 25. EP 1027887 August 16, 2000 **EPA** EPA EP 1027886 August 16, 2000 26. March 17, 1999 **EPA** EP 901786 27. Great Britain GB 2,306,885 May 14, 1997 28. Yes March 4, 1997 Japan JP 09059159 JDA 29. OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) Barker et al. "Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer" Bioorg Med Chem Lett.11(14): 1911-1914 JDA Hasegawa et al. "Supersaturation mechanism of drugs from solid dispersions with enteric coating agents" Chem Pharm JDA Bull (Tokyo) 36(12): 4941-4950 (1988) Herbst et al. "Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally welltolerated and has activity in non-small-cell lung cancer and other solid tumors: Results of a phase I trial" J Clin Oncol JDA 20(18): 3815-3825 (2002) Date Considered Examiner 07/18/2006 /James Anderson/ Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION		Attorney Docket No. 056291-5174-US			Application No. 10/505,231					
	J)	Use several sheets if necessary)	Applicar	Applicants: GELLERT et al.  Filing Date: August 19, 2004			PAGE 2 of 2			
		PTO Form 1449	Filing				Group Art Unit: 1615			
		U.S. PA	TENT DO	OCUMENTS						
Initial		Document No. Date		Name	Class	Sub-Class	Filing Date			
	┼				+	-				
	<del> </del>									
			PATENT	DOCUMENTS						
	<u> </u>	Document No. Date		Country	Class	Sub-Class	Translation			
	┼		<del></del>		+	<del></del>				
	<del> </del>	+			+	+				
	<u></u>									
	Laa	OTHER DOCUMENTS (Include					** 100 220 220			
JDA	33.	Iervolino et al. "Membrane penetration enha	ancement	of ibuproten using	supersatura	ation" Int. J.	Pharm. 198: 229-238			
<del></del>	34.	Jervolino et al. "Penetration enhancement of	f ibuprofe	n from supersatura	ted solution	ns through h	uman skin" Int. J.			
	<u> </u>	Pharm. 212: 131-141 (2001)		•						
	35.	Ikeda et al. Chem. Pharm. Bull., 42(11): 23			·" Com		11 11 0 11 12 12 12 12 12 12 12 12 12 12 12 12			
7100	36.	Lawrence et al. "Small-molecule tyrosine kinase inhibitors as radiosensitizers" Seminars in Radiation Oncology 12(3) 33-36 (2002)								
	37.	Loftsson et al. "The effect of water-soluble polymers on aqueous solubility of drugs" Int. J. Pharm. 127: 293-296								
	<u> </u>	(1996)								
	38.	16(3): 225-230 (2004)								
	39.	Megrab et al. "Oestradiol permeation through human skin and silastic membrane: effects of propylene glycol and supersaturation" J. Control Rel 36: 277-294 (1995)								
	40.									
	41.	<del> </del>								
	42.									
	43.	Ranson et al. "ZD1839, a Selective Oral Er Tolerated and Active in Patients With Solid Oncology 20(9): 2240-2250 (2002)	pidermal G							
$\overline{\mathbf{V}}$	44.	Usui et al. "Inhibitory Effects of Water-Solu (1997)	uble Polyn	ners on Precipitation	on of RS-83	359" Int. J. P	harm. 154: 59-66			
JDA	45.	Wakeling et al. "An Orally Active Inhibitor Cancer Research 62: 5749-5754 (2002)	of Epider	mal Growth Factor	Signaling	with Potenti	ial for Cancer Therapy			
		•								
	├									
	<del> </del>				<del></del>					
	$\vdash$						<del></del>			
xaminer		/James Anderson/ Date C	Considered	07/18/20	06					
	<del>. v</del>	al if reference considered, whether or not citat	tion is in s		ADED 600.	draw line th				